Skip to main content

Advertisement

SpringerLink
Log in

Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Portal branch ligation (PBL) can be performed before major hepatic resection of colorectal liver metastases (mCRC) to increase the remnant liver mass. However, PBL may also stimulate mCRC growth through hepatic arterial hyperperfusion and growth factor release. Herein, we studied whether hepatic arterial infusion (HAI) of the mTOR-inhibitor temsirolimus (Tem) is capable of inhibiting the growth of colorectal liver metastases after PBL. WAG/Rij rats were randomized to four groups (n = 6 each) and underwent subcapsular implantation of 5 × 105 CC531 cells into the left liver lobe. The animals of two groups underwent simultaneous PBL of the tumour bearing liver lobe. Ten days later animals underwent a HAI either of temsirolimus (Tem and PBL Tem) or saline solution (Sham and PBL Sham). Tumour size was analyzed at days 10 and 13 using three-dimensional ultrasound. In Sham controls tumour volume increased by 43 %. After PBL Sham tumour volume increased by 52 %. In contrast, in animals undergoing HAI of temsirolimus the tumour growth was not only completely inhibited, but tumour volume was found decreased, irrespective of PBL. After HAI of temsirolimus immunohistochemistry revealed an increased cleaved caspase-3 activity, indicating stimulation of apoptotic cell death. In parallel temsirolimus treatment was associated with a significant reduction of PECAM-1 positive cells within the tumour tissue, implying a reduced tumour vascularisation. HAI of temsirolimus is capable of inhibiting the growth of CC531 colorectal rat liver metastases also after PBL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chu E (2012) An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorect Cancer 11(1):1–13

    Article  CAS  Google Scholar 

  2. Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77(11):1241–1246

    Article  CAS  PubMed  Google Scholar 

  3. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410

    Article  CAS  PubMed  Google Scholar 

  4. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P, Yamazaki S, Hasegawa H, Ozaki H (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107(5):521–527

    CAS  PubMed  Google Scholar 

  5. Iida H, Aihara T, Ikuta S, Yoshie H, Yamanaka N (2012) Comparison of percutaneous transhepatic portal vein embolization and unilateral portal vein ligation. World J Gastroenterol 18(19):2371–2376

    Article  PubMed Central  PubMed  Google Scholar 

  6. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P (2003) Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44(1):98–102

    CAS  PubMed  Google Scholar 

  7. Elias D, De Baere T, Roche A, Mducreux Leclere J, Lasser P (1999) During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86(6):784–788

    Article  CAS  PubMed  Google Scholar 

  8. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Ohta K, Yamaguchi T, Matsubara T, Takahashi T, Nakajima T, Muto T, Ikari T, Yanagisawa A, Kato Y (2001) Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 34(2):267–272

    Article  CAS  PubMed  Google Scholar 

  9. van Gulik TM, van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M, van Delden OM, Laméris JS, Gouma DJ (2008) Controversies in the use of portal vein embolization. Dig Surg 25(6):436–444

    Article  PubMed  Google Scholar 

  10. Fasolo A, Sessa C (2012) Targeting mTOR Pathways in human malignancies. Curr Pharm 18(19):2766–2777

    Article  CAS  Google Scholar 

  11. Wander SA, Hennessy BT, Slingerland JM (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121(4):1231–1241

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Power DG, Healey-Bird BR, Kemeny NE (2008) Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 7(4):247–259

    Article  CAS  PubMed  Google Scholar 

  13. Seront E, Van den Eynde M (2012) Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases? Clin Colorect Cancer 11(3):177–184

    Article  CAS  Google Scholar 

  14. Sperling J, Schäfer T, Ziemann C, Benz-Weißer A, Kollmar O, Schilling MK, Menger MD (2012) Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metast 29(2):91–99

    Article  CAS  Google Scholar 

  15. Boni JP, Hug B, Leister C, Sonnichsen D (2009) Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 36(suppl 3):18–25

    Article  Google Scholar 

  16. Workman P, Twentyman P, Balkwill F et al (1998) United Kingdom Co-ordinating Committe on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd edn). Br J Cancer 77:1–10

    Google Scholar 

  17. Institute of Laboratory Animal Resources, National Research Council (1996) Guide for the care and use of laboratory animals. NIH guide, vol 25, p. 28

  18. Reinacher-Schick AC, Bechstein WO (2007) Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology. Internist 48(1):51–58

    Article  PubMed  Google Scholar 

  19. Khatri VP, Chee KG, Petrelli NJ (2007) Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 16(1):71–83

    Article  PubMed  Google Scholar 

  20. de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM (2011) Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 98(6):825–834

    Article  PubMed  Google Scholar 

  21. Lin KJ, Liao CH, Hsiao IT, Yen TC, Chen TC, Jan YY, Chen MF, Yeh TS (2009) Improved hepatocyte function of future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting. Surgery 145(2):202–211

    Article  PubMed  Google Scholar 

  22. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, Sauvanet A (2003) Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237(2):208–217

    PubMed Central  PubMed  Google Scholar 

  23. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, Hawkins IF, Vauthey JN (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237(5):686–691 (discussion 691–693)

    PubMed Central  PubMed  Google Scholar 

  24. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P (2004) A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240(6):1037–1049 (discussion 1049–1051)

    Article  PubMed Central  PubMed  Google Scholar 

  25. van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M, van Delden OM, Gouma DJ, Bennink RJ, Laméris JS, van Gulik TM (2009) Volumetric and functional recovery of the remnant liver after major liver resection with prior portal vein embolization : recovery after PVE and liver resection. J Gastrointest Surg 13(8):1464–1469

    Article  PubMed Central  PubMed  Google Scholar 

  26. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247(1):49–57

    Article  PubMed  Google Scholar 

  27. Rozga J, Tanaka N, Jeppsson B, Hägerstrand I, Bengmark S (1985) Tumor growth in liver atrophy and growth. An experimental study in rats. Eur J Cancer Clin Oncol 21(1):135–140

    Article  CAS  PubMed  Google Scholar 

  28. Bai ZJ, Feng XS (1994) The effect of ligation of portal branch on the growth of implanted tumor of the liver in rats. J Tongji Med Univ 14(4):239–241

    Article  CAS  PubMed  Google Scholar 

  29. Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y (2011) Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery 149(4):496–503

    Article  PubMed  Google Scholar 

  30. Sakai N, Clarke CN, Schuster R, Blanchard J, Tevar AD, Edwards MJ, Lentsch AB (2010) Portal vein ligation accelerates tumor growth in ligated, but not contralateral lobes. World J Gastroenterol 16(30):3816–3826

    Article  PubMed Central  PubMed  Google Scholar 

  31. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD (2007) Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol Gastrointest Liver Physiol 292(6):G1534–G1542

    Article  CAS  PubMed  Google Scholar 

  32. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD (2010) Tumour growth following portal branch ligation in an experimental model of liver metastases. Br J Surg 97(6):917–926

    Article  CAS  PubMed  Google Scholar 

  33. Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J (2006) Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 10(3):365–370

    Article  PubMed  Google Scholar 

  34. Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, Sofocleous CT, D’Angelica M, Getrajdman GI, DeMatteo R, Kemeny NE, Fong Y (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247(3):451–455

    Article  PubMed  Google Scholar 

  35. de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM (2009) Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol 16(2):423–430

    Article  PubMed  Google Scholar 

  36. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–985

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Burkel W (1970) The fine structure of the terminal branches of the hepatic arterial system of the rat. Anatom Rec 167:329–349

    Article  CAS  Google Scholar 

  38. Gonda T, Ishida H, Yoshinaga K, Sugihara K (2000) Microvasculature of small liver metastases in rats. J Surg Res 94(1):43–48

    Article  CAS  PubMed  Google Scholar 

  39. Cohen AD, Kemeny NE (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8(6):553–566

    Article  PubMed  Google Scholar 

  40. Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 8(3):CD007823

    Google Scholar 

  41. Pohlen U, Buhr HJ, Berger G, Ritz JP, Holmer C (2012) Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model. Invest New Drugs 30(3):927–935

    Article  CAS  PubMed  Google Scholar 

  42. Pohlen U, Reszka R, Buhr HJ, Berger G (2011) Hepatic arterial infusion in the treatment of liver metastases with PEG liposomes in combination with degradable starch microspheres (DSM) increases tumor 5-FU concentration. An animal study in CC-531 liver tumor-bearing rats. Anticancer Res 31(1):147–152

    CAS  PubMed  Google Scholar 

  43. Ballou LM, Lin RZ (2008) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1(1–4):27–36

    Article  PubMed Central  PubMed  Google Scholar 

  44. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688

    Article  CAS  PubMed  Google Scholar 

  45. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, Jauch KW, Geissler EK (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18(1):89–94

    Article  CAS  PubMed  Google Scholar 

  46. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135

    Article  CAS  PubMed  Google Scholar 

  47. Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Di Scala L, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E (2011) Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol 6(12):2120–2129

    Article  PubMed  Google Scholar 

  48. Frost P, Berlanger E, Mysore V, Hoang B, Shi Y, Gera J, Lichtenstein A (2013) Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol 2013:897025

    Article  PubMed Central  PubMed  Google Scholar 

  49. Schedel F, Pries R, Thode B, Wollmann B, Wulff S, Jocham D, Wollenberg B, Kausch I (2011) mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep 25(3):763–768

    CAS  PubMed  Google Scholar 

  50. Sperling J, Ziemann C, Gittler A, Benz-Weißer A, Menger MD, Kollmar O (2013) Hepatic arterial infusion of temsirolimus inhibits tumor growth of colorectal rat liver metastases even after a growth stimulating procedure like liver resection. J Surg Res 185(2):587–594

    Article  CAS  PubMed  Google Scholar 

  51. Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C (2013) mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 19(5):1180–1189

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical and Experimental Surgery, University of Saarland, Homburg, Saarland, Germany

    Jens Sperling, Christian Ziemann, Anika Gittler, Anna Benz-Weißer, Michael D. Menger & Otto Kollmar

  2. Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Str. 40, 37099, Göttingen, Germany

    Jens Sperling & Otto Kollmar

Authors
  1. Jens Sperling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Ziemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anika Gittler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Benz-Weißer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael D. Menger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Otto Kollmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Sperling.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sperling, J., Ziemann, C., Gittler, A. et al. Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation. Clin Exp Metastasis 32, 313–321 (2015). https://doi.org/10.1007/s10585-015-9707-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-015-9707-4

Keywords

Search

Navigation